Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 24 results.
User Information
Export Records
  1. 1.   Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma
  2. Fu, Ying; Urban, Daniel J.; Nani, Roger R.; Zhang, Yi-Fan; Li, Nan; Fu, Haiying; Shah, Hamzah; Gorka, Alexander P.; Guha, Rajarshi; Chen, Lu; Hall, Matthew D.; Schnermann,Martin; Ho, Mitchell
  3. Hepatology (Baltimore, Md.). 2019, AUG; 70(2): 563-576.
  1. 2.   Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy
  2. Bera, Tapan K.; Liu, Wenlong; Leshem, Jasmin; King, Emily; Kozlov,Serguei; Pastan, Ira
  3. Journal of immunotherapy (Hagerstown, Md. : 1997). 2019, May; 42(4): 119-125.
  1. 3.   Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors
  2. El-Behaedi, Salma; Landsman, Rebekah; Rudloff, Michael; Kolyvas, Emily; Albalawy, Rakan; Zhang, Xianyu; Bera, Tapan; Collins, Keith; Kozlov, Serguei; Alewine, Christine
  3. Toxins. 2018, Nov; 10(11): pii: E447.
  1. 4.   5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox
  2. Müller, Fabian; Cunningham, Tyler; Stookey, Stephanie; Tai, Chin-Hsien; Burkett, Sandra; Jailwala, Parthav; Stetler Stevenson, Maryalice; Cam, Margaret C; Wayne, Alan S; Pastan, Ira
  3. Proceedings of the National Academy of Sciences of the United States of America. 2018, Feb 20; 115(8): E1867-E1875.
  1. 5.   Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
  2. Li, Nan; Fu, Haiying; Hewitt, Stephen M; Dimitrov, Dimiter; Ho, Mitchell
  3. Proceedings of the National Academy of Sciences of the United States of America. 2017, Aug 8; 114(32): E6623-E6631.
  1. 6.   HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
  2. Zielinski, R.; Lyakhov, I.; Hassan, M.; Kuban, M.; Shafer-Weaver, K.; Gandjbakhche, A.; Capala, J.
  3. Clinical Cancer Research. 2011, Aug; 17(15): 5071-5081.
  1. 7.   A novel high-affinity human monoclonal antibody to mesothelin
  2. Ho, M.; Feng, M. Q.; Fisher, R. J.; Rader, C.; Pastan, I.
  3. International Journal of Cancer. 2011, May; 128(9): 2020-2030.
  1. 8.   A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity
  2. Feng, Y.; Xiao, X. D.; Zhu, Z. Y.; Streaker, E.; Ho, M.; Pastan, I.; Dimitrov, D. S.
  3. Molecular Cancer Therapeutics. 2009, May; 8(5): 1113-1118.
  1. 9.   Aprotease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
  2. Weldon, J. E.; Xiang, L. M.; Chertov, O.; Margulies, I.; Kreitman, R. J.; FitzGerald, D. J.; Pastan, I.
  3. Blood. 2009 113(16): 3792-3800.
  1. 10.   Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients
  2. Onda, M.; Nagata, S.; FitzGerald, D. J.; Beers, R.; Fisher, R. J.; Vincent, J. J.; Lee, B.; Nakamura, M.; Hwang, J. L.; Kreitman, R. J.; Hassan, R.; Pastan, I.
  3. Journal of Immunology. 2006, Dec; 177(12): 8822-8834.
  1. 11.   Efficient killing of CD22(+) tumor cells by a humanized diabody-RNase fusion protein
  2. Krauss, J.; Arndt, M. A. E.; Vu, B. K.; Newton, D. L.; Seeber, S.; Rybak, S. M.
  3. Biochemical and Biophysical Research Communications. 2005, JUN 3; 331(2): 595-602.
  1. 12.   Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme
  2. Krauss, J.; Arndt, M. A. E.; Vu, B. K.; Newton, D. L.; Rybak, S. M.
  3. British Journal of Haematology. 2005, MAR; 128(5): 602-609.
  1. 13.   A dimeric angiogenin immunofusion protein mediates selective toxicity towards CD22(+) tumor cells
  2. Arndt, M. A. E.; Krauss, J.; Vu, B. K.; Newton, D. L.; Rybak, S. M.
  3. Journal of Immunotherapy. 2005, MAY-JUN; 28(3): 245-251.
  1. 14.   A potent anti-HIV immunotoxin blocks spreading infection by primary HIV type 1 isolates in multiple cell types
  2. Lueders, K. K.; De Rosa, S. C.; Valentin, A.; Pavlakis, G. N.; Roederer, M.; Hamer, D. H.
  3. Aids Research and Human Retroviruses. 2004 20(2): 145-150.
  1. 15.   Preparation of recombinant RNase single-chain antibody fusion proteins
  2. Newton, D. L.; Rybak, S. M.
  3. Molecular Biotechnology. 2002 20(1): 63-76.
  1. 16.   Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics
  2. Hursey, M.; Newton, D. L.; Hansen, H. J.; Ruby, D.; Goldenberg, D. M.; Rybak, S. M.
  3. Leukemia & Lymphoma. 2002 43(5): 953-959.
  1. 17.   Testing of new agents in childhood cancer preclinical models: Meeting summary
  2. Houghton, P. J.; Adamson, P. C.; Blaney, S.; Fine, H. A.; Gorlick, R.; Haber, M.; Helman, L.; Hirschfeld, D.; Hollingshead, M. G.; Israel, M. A.; Lock, R. B.; Maris, J. M.; Merlino, G.; Patterson, W.; Reynolds, C. P.; Shannon, K.; Yu, A.; Yu, J.; Smith, M. A.
  3. Clinical Cancer Research. 2002 8(12): 3646-3657.
  1. 18.   Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma
  2. Huhn, M.; Sasse, S.; Tur, M. K.; Matthey, B.; Schinkothe, T.; Rybak, S. M.; Barth, S.; Engert, A.
  3. Cancer Research. 2001 61(24): 8737-8742.
  1. 19.   Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents
  2. Newton, D. L.; Hansen, H. J.; Liu, H. T.; Ruby, D.; Iordanov, M. S.; Magun, B. E.; Goldenberg, D. M.; Rybak, S. M.
  3. Critical Reviews in Oncology Hematology. 2001 39(1-2): 79-86.
  1. 20.   Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA
  2. Newton, D. L.; Rybak, S. M.
  3. Expert Opinion on Biological Therapy. 2001 1(6): 995-1003.
  1. 21.   Phase I trial of recombinant immunotoxin anti-Tac(Fv)PE38 (LMB-2) in patients with hematologic malignancies
  2. Kreitman, R. J.; Wilson, W. H.; White, J. D.; Stetler-Stevenson, M.; Jaffe, E. S.; Giardina, S.; Waldmann, T. A.; Pastan, I.
  3. Journal of Clinical Oncology. 2000 18(8): 1622-1636.
  1. 22.   Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice
  2. Newton, D. L.; Pollock, D.; DiTullio, P.; Echelard, Y.; Harvey, M.; Wilburn, B.; Williams, J.; Hoogenboom, H. R.; Raus, J. C. M.; Meade, H. M.; Rybak, S. M.
  3. Journal of Immunological Methods. 1999 231(1-2): 159-167.
  1. 23.   Retrovirus-Mediated Transfer of the Herpes Simplex Type I Thymidine Kinase Gene in Alloreactive T Lymphocytes
  2. Contassot, E.; Ferr, C.; Certoux, J. M.; Reynolds, C. W.; Jacob, W.; Chiang, Y. W.; Cahn, J. Y.; Herve, P.; Tiberghien, P.
  3. Human Gene Therapy. 1998 9(1): 73-80.
  1. 24.   Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphomas
  2. Hirano, A.; Funakoshi, S.; Epstein, A.; Longo, D.; Murphy, W.
  3. Annual Meeting of the American Association for Cancer Research. 1997, 38 A2707.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel